Actively Recruiting
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
Led by UNC Lineberger Comprehensive Cancer Center · Updated on 2026-04-22
36
Participants Needed
1
Research Sites
403 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to test the safety of using T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (CAR.B7-H3T cells) in patients with glioblastoma. CAR.B7-H3T cells treatment has not been tested in humans and is not an approved treatment by the Food and Drug Administration for glioblastoma.
CONDITIONS
Official Title
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Karnofsky score greater than 60%
- Diagnosis of recurrent supratentorial or infratentorial glioblastoma multiforme based on MRI criteria
- Previous resection or biopsy at initial diagnosis
- Completed at least 4005 cGy of radiation with concurrent temozolomide
- No prior or current treatment with antiangiogenic agents such as bevacizumab
- Female participants of childbearing potential agree to use two effective contraception methods or abstain from heterosexual activity from consent until 6 months after study treatment
- Male participants with female partners have had vasectomy or agree to use contraception from first dose until 3 months after last infusion
- Willing and able to comply with study procedures as judged by the investigator
You will not qualify if you...
- Pregnant or lactating individuals
- Prior or concurrent malignancies that may interfere with safety or efficacy assessments
- Active infection with HIV, hepatitis B, hepatitis C, or HTLV1/2
- Contraindication to MRI contrast agents or inability to undergo MRI due to incompatible implants
- Previous treatment with chimeric antigen receptor T cell therapy for glioblastoma
- Disseminated disease involving brainstem, cerebellum, or spinal cord
- Previous implantation of carmustine wafers or brachytherapy for glioma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
Research Team
C
Catherine Cheng
CONTACT
C
Caroline Babinec
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here